Literature DB >> 8740235

Cytochrome c oxidase deficiencies in the muscle of patients with inflammatory myopathies.

P Chariot1, E Ruet, F J Authier, D Labes, F Poron, R Gherardi.   

Abstract

We studied mitochondrial function in inflammatory myopathies, using cytochrome c oxidase (COX) reaction on muscle biopsy samples from 30 patients (15 with dermatomyositis, 12 with polymyositis, and 3 with inclusion body myositis) and 30 age-matched controls. We also performed immunocytochemistry for COX II and COX IV subunits in 7 of these patients who had COX deficiency. COX-deficient fibers were a constant finding in patients or controls older than 65 years and the percentage of COX-deficient fibers correlated with age in both patients and controls. Focal COX deficiency was found in 24 patients (13 of 15 with dermatomyositis, 8 of 12 with polymyositis, and 3 of 3 with inclusion body myositis) and 18 controls. The percentages of COX-deficient fibers were higher in patients with inflammatory myopathies (range: 0-4.7%; mean: 1.2%) than in age-matched controls (range: 0-1.9%; mean: 0.4%) (P < 0.01). In the subgroup of patients under age 65, COX-deficient fibers were more frequent in dermatomyositis than in polymyositis (mean: 0.8% vs 0.2%, P = 0.02). In patients with dermatomyositis, capillary loss correlated positively with COX deficiency (P < 0.02). Immunocytochemistry for COX II and IV showed that 82% of COX-negative fibers were COX II-negative and 26% were COX IV-negative, suggesting that proteins encoded by mitochondrial DNA are predominantly, but not exclusively, involved in COX deficiency. We conclude that mitochondrial dysfunction and COX deficiency can occur in inflammatory myopathies. Such a mitochondrial dysfunction is not solely related to the aging process. We suggest that muscle ischemia contributes to mitochondrial dysfunction in dermatomyositis.

Entities:  

Mesh:

Year:  1996        PMID: 8740235     DOI: 10.1007/s004010050462

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  8 in total

1.  Impaired redox status and cytochrome c oxidase deficiency in patients with polymyalgia rheumatica.

Authors:  P Chariot; X Chevalier; M Yerroum; I Drogou; F J Authier; R Gherardi
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

2.  Mitochondrial abnormalities in dermatomyositis: characteristic pattern of neuropathology.

Authors:  Mohammed I Alhatou; John T Sladky; Omar Bagasra; Jonathan D Glass
Journal:  J Mol Histol       Date:  2004-08       Impact factor: 2.611

3.  Diagnostic evaluation of rhabdomyolysis.

Authors:  Jessica R Nance; Andrew L Mammen
Journal:  Muscle Nerve       Date:  2015-03-14       Impact factor: 3.217

Review 4.  Polymyositis with mitochondrial pathology or atypical form of sporadic inclusion body myositis: case series and review of the literature.

Authors:  George K Papadimas; Charalampos Kokkinis; Sophia Xirou; Margarita Chrysanthou; Evangelia Kararizou; Constantinos Papadopoulos
Journal:  Rheumatol Int       Date:  2019-05-04       Impact factor: 2.631

5.  Investigation of splicing changes and post-translational processing of LMNA in sporadic inclusion body myositis.

Authors:  Yue-Bei Luo; Chalermchai Mitrpant; Russell Johnsen; Vicki Fabian; Merrilee Needham; Sue Fletcher; Steve D Wilton; Frank L Mastaglia
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

6.  Analysis of respiratory chain regulation in roots of soybean seedlings

Authors: 
Journal:  Plant Physiol       Date:  1998-07       Impact factor: 8.340

7.  Mitochondrial dysfunction in myofibrillar myopathy.

Authors:  Amy E Vincent; John P Grady; Mariana C Rocha; Charlotte L Alston; Karolina A Rygiel; Rita Barresi; Robert W Taylor; Doug M Turnbull
Journal:  Neuromuscul Disord       Date:  2016-08-10       Impact factor: 4.296

8.  Idiopathic inflammatory myopathy human derived cells retain their ability to increase mitochondrial function.

Authors:  Carla Basualto-Alarcón; Félix A Urra; María Francisca Bozán; Fabián Jaña; Alejandra Trangulao; Jorge A Bevilacqua; J César Cárdenas
Journal:  PLoS One       Date:  2020-11-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.